BioPharmSignal logoBioPharmSignal

Biotech News

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals (CNTA)Centessa PharmaceuticalsEarnings

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients

Related news

CNTACentessa Pharmaceuticals2025-08-12 11:01 EST

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

CNTACentessa Pharmaceuticals2026-01-14 22:00 EST

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

View all latest news

Centessa Pharmaceuticals

Centessa Pharmaceuticals is a platform biopharma company incubating focused therapeutic programs across multiple disease areas. Its model emphasizes capital allocation, program selection, and broad platform optionality.

Recent company news

CNTACentessa Pharmaceuticals2026-03-31 10:45 EST

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

CNTACentessa Pharmaceuticals2026-02-03 13:00 EST

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

CNTACentessa Pharmaceuticals2026-01-14 22:00 EST

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

CNTACentessa Pharmaceuticals2025-12-11 12:00 EST

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

CNTACentessa Pharmaceuticals2025-11-12 01:40 EST

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Stock data

Close
40.50 USD
Market cap
6.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States